Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-Breast-Cancer-2022-1000x250

Click on the links below to access the Industry Sponsored Satellite Symposia Invitations. 

Tumor Board: How the Experts Approach Personalized Care Plans in ER-Positive Breast Cancer

01-Tumor-Board-SANOFI-GENZYME-Thumb

Tuesday, 11:30 – 12:30
View the satellite invitation

Triple-Negative Breast Cancer: See Beyond the Negatives

02-Triple-Negative-Breast-Cancer-See-Beyond-the-Negatives-GILEAD-Thumb

Tuesday, 11:30 – 12:30
View the satellite invitation

Controversies in Breast Cancer

04-Controversies-in-Breast-Cancer-ASTRAZENECA-Thumb

Tuesday, 11:30 – 12:30
View the satellite invitation

The Opportunities and Challenges of Targeting Pathways in HER2-Positive BC beyond HER2

05-The-Opportunities-and-Challenges-of-Targeting-Pathways-in-HER2-Positive-BC-beyond-HER2-ROCHE-Thumb

Tuesday, 18:15 – 19:15
View the satellite invitation

Broadening Horizons in HER2- Advanced Breast Cancer

09-Broadening-Horizons-in-HER2-Advanced-Breast-Cancer-PFIZER-ONCOLOGY-Thumb

Wednesday, 13:00 – 14:00
View the satellite invitation

Treatment Sequencing in HER2-Positive Metastatic Breast Cancer: From Guidelines to Clinical Practice

10-Treatment-Sequencing-in-HER2-Positive-Metastatic-Breast-Cancer-SEAGEN-Thumb

Wednesday, 13:00 – 14:00
View the satellite invitation

What about HER Journey? Let’s Focus on HER2+ Early Breast Cancer

12-What-about-HER-Journey-Lets-Focus-on-HER2-Early-Breast-Cancer-PIERRE-FABRE-Thumb

Wednesday, 13:00 – 14:00
View the satellite invitation

HR+/HER2− Breast Cancer: How the Latest Data Help Inform Treatment Decisions

13-HR-HER2-Breast-Cancer-How-the-Latest-Data-Help-Inform-Treatment-Decisions-NOVARTIS-Thumb

Wednesday, 18:30 – 19:30
View the satellite invitation

Advancements in Immune-Oncology for Triple Negative Breast Cancer

14-Advancements-in-Immune-Oncology-for-Triple-Negative-Breast-Cancer-MSD-Thumb

Wednesday, 18:30 – 19:30
View the satellite invitation

A New Horizon for HER2 Expressing Breast Cancer

15-Advancements-in-Immune-Oncology-for-Triple-Negative-Breast-Cancer-DAIICHI-SANKYO-ASTRAZENECA-Thumb

Wednesday, 18:30 – 19:30
View the satellite invitation

Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice

17-Aiming-to-Minimize-the-Risk-of-Recurrence-in-Early-Breast-Cancer-LILLY-Thumb

Thursday, 12:30 – 13:30
View the satellite invitation

Special Delivery: ADC Targets for Breast Cancer (BC)

18-Special-Delivery-ADC-Targets-for-Breast-Cancer-BC-DAIICHI-SANKYO-Thumb

Thursday, 12:30 – 13:30
View the satellite invitation

Cases Discussions: In the Current MBC Treatment Landscape of HR+/HER2- And TNBC, What’s the Role of Chemotherapy? - This Promotional Event Is for HCPs Only

19-Cases-Discussions-EISAI-Thumb

Thursday, 12:30 – 13:30
View the satellite invitation

Please note: The European Society for Medical Oncology (ESMO) does not endorse any of the companies, or their products/services, that have sponsored these links.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.